BAX Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-mediated gene disruption model in the human Jurkat T-cell line, supplied as a polyclonal population. The polyclonal format avoids clonal selection, offering a heterogeneous pool of BAX loss-of-function variants suitable for pooled functional assays. This product is designed for apoptosis research, pathway analysis, and drug screening without the need for single-cell cloning.
Jurkat cells, derived from acute T-cell leukemia, are suspension-adapted and IL-2-independent with a p53 mutant background. They serve as a classic model for T-cell signaling and apoptosis, enabling the study of p53-independent cell death mechanisms. The mutant p53 status makes them distinct from many other cancer cell lines, allowing focus on mitochondrial apoptosis without confounding wild-type p53 responses.
BAX encodes a pro-apoptotic BCL2 family member that functions as a key effector of the intrinsic apoptosis pathway. It is activated by upstream BH3-only proteins such as PUMA, BIM, NOXA, and tBID, which are regulated by p53, JNK, and survival signals from BCL2, BCL2L1, and MCL1. Upon activation, BAX translocates to mitochondria, oligomerizes, and interacts with VDAC1 and BAK1 to permeabilize the outer membrane. This releases cytochrome c and SMAC/DIABLO, leading to APAF1-dependent caspase-9 activation and subsequent caspase-3 cleavage, executing apoptosis. Thus, BAX integrates survival and death signals at the mitochondrial gate.
In Jurkat cells, BAX knockout disrupts mitochondrial apoptosis downstream of diverse stimuli, providing a clean background to assess BAX-dependent death. This model is particularly relevant for T-cell leukemia research, as Jurkat cells are p53-mutant and often used to evaluate drug resistance, BH3 mimetics like venetoclax, and the role of anti-apoptotic BCL2 members. BAX deficiency allows dissection of alternative apoptotic pathways and resistance mechanisms in hematopoietic cancers.
Key applications encompass Annexin V/PI flow cytometry, caspase-3/7 activity measurements, cytochrome c release assays, mitochondrial membrane potential monitoring (JC-1, TMRM), and Western blotting for BAX and apoptosis markers. The polyclonal population is compatible with drug sensitivity screens, RT-qPCR quantification of BAX transcripts, and immunoprecipitation studies of BAX interactions with BCL2 or BCL2L1. This tool supports cancer biology, immunology, and drug discovery initiatives. For additional information, please contact Ascent Research.
